These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 17262062

  • 61. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.
    Perfetti V, Siena S, Palladini G, Bregni M, Di Nicola M, Obici L, Magni M, Brunetti L, Gianni AM, Merlini G.
    Haematologica; 2006 Dec; 91(12):1635-43. PubMed ID: 17145600
    [Abstract] [Full Text] [Related]

  • 62. Autologous and allogeneic transplantation for multiple myeloma at a single centre.
    Couban S, Stewart AK, Loach D, Panzarella T, Meharchand J.
    Bone Marrow Transplant; 1997 Apr; 19(8):783-9. PubMed ID: 9134169
    [Abstract] [Full Text] [Related]

  • 63.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 64. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
    Worel N, Schulenburg A, Mitterbauer M, Keil F, Rabitsch W, Kalhs P, Gisslinger H, Raderer M, Geissler K, Höcker P, Zielinski CC, Oberbauer R, Greinix HT.
    Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526
    [Abstract] [Full Text] [Related]

  • 65. Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma.
    Bruno B, Sorasio R, Patriarca F, Montefusco V, Guidi S, Busca A, Scimé R, Console G, Milone G, Marotta G, Dominietto A, Giaccone L, Rotta M, Falda M, Bacigalupo A, Bosi A, Corradini P, Fanin R, Pollichieni S, Boccadoro M, Gruppo Italiano Trapianto Midollo Osseo.
    Eur J Haematol; 2007 Apr; 78(4):330-7. PubMed ID: 17331132
    [Abstract] [Full Text] [Related]

  • 66. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
    Vogl DT, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ, Tsai DE, Perl A, Loren AW, Goldstein SC, Nasta SD, Andreadis C, Mangan PA, Hummel K, Siegel DL, Glatstein E, Stadtmauer EA.
    Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
    [Abstract] [Full Text] [Related]

  • 67. [Encouraging results of stem cell transplantation following a melphalan-preceding intensified preparative regimen for refractory acute leukemia in children].
    Inoue M, Yasui M, Sawada A, Koyama M, Kondo O, Miyamura T, Higuchi B, Kouroki M, Ishihara T, Kawa K.
    Rinsho Ketsueki; 2007 Nov; 48(11):1470-7. PubMed ID: 18080504
    [Abstract] [Full Text] [Related]

  • 68. BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma.
    Talamo G, Claxton DF, Dougherty DW, Ehmann CW, Sivik J, Drabick JJ, Rybka W.
    Bone Marrow Transplant; 2009 Aug; 44(3):157-61. PubMed ID: 19204716
    [Abstract] [Full Text] [Related]

  • 69. Single-centre experience with nonmyeloablative allogeneic stem cell transplantation in patients with multiple myeloma: prolonged remissions induced.
    van Dorp S, Meijer E, van de Donk NW, Dekker AW, Nieuwenhuis K, Minnema MC, Petersen E, Schutgens R, Verdonck LF, Lokhorst HM.
    Neth J Med; 2007 May; 65(5):178-84. PubMed ID: 17519513
    [Abstract] [Full Text] [Related]

  • 70. Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation in patients with poor-prognosis solid tumors - Bulgarian experience.
    Avramova B, Jordanova M, Michailov G, Konstantinov D, Christosova I, Bobev D.
    J BUON; 2006 May; 11(4):433-8. PubMed ID: 17309174
    [Abstract] [Full Text] [Related]

  • 71. Limited feasibility of double transplant in multiple myeloma: results of a multicenter study on 153 patients aged <65 years.
    Corso A, Mangiacavalli S, Barbarano L, Alessandrino EP, Cairoli R, Morra E, Lazzarino M, HOST Group.
    Cancer; 2007 Jun 01; 109(11):2273-8. PubMed ID: 17440982
    [Abstract] [Full Text] [Related]

  • 72. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?
    Mehta J, Tricot G, Jagannath S, Ayers D, Singhal S, Siegel D, Desikan K, Munshi N, Fassas A, Mattox S, Vesole D, Crowley J, Barlogie B.
    Bone Marrow Transplant; 1998 May 01; 21(9):887-92. PubMed ID: 9613780
    [Abstract] [Full Text] [Related]

  • 73. Autologous stem cell transplantation for relapsed and primary refractory myeloma.
    Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Lust JA, Greipp PR, Therneau TM, Kyle RA, Litzow MR, Gertz MA.
    Bone Marrow Transplant; 1999 Jun 01; 23(12):1267-72. PubMed ID: 10414914
    [Abstract] [Full Text] [Related]

  • 74. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
    Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C, Dib M, Guillerm G, Salles B, Eschard JP, Lenain P, Casassus P, Azaïs I, Decaux O, Garderet L, Mathiot C, Fontan J, Lafon I, Virion JM, Moreau P.
    J Clin Oncol; 2009 Aug 01; 27(22):3664-70. PubMed ID: 19451428
    [Abstract] [Full Text] [Related]

  • 75. Impact of early relapse after auto-SCT for multiple myeloma.
    Kumar S, Mahmood ST, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Dingli D, Rajkumar SV, Litzow MR, Gertz MA.
    Bone Marrow Transplant; 2008 Sep 01; 42(6):413-20. PubMed ID: 18587435
    [Abstract] [Full Text] [Related]

  • 76. Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma.
    García-Sanz R, Hernández JM, Sureda A, García-Laraña J, Prósper F, Alegre A, Bárez A, Mateos MV, San Miguel JF.
    Hematol Oncol; 2006 Dec 01; 24(4):205-11. PubMed ID: 17006969
    [Abstract] [Full Text] [Related]

  • 77.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 78.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 79. The first 2 years of clinical experience with peripheral blood stem cell transplantation for various hematological malignancies: results from a single Baskent University Center.
    Ozdogu H, Boga C, Kizilkilic E, Kozanoglu I, Karakus S, Sahin FI, Unalan D, Haberal M.
    Transplant Proc; 2007 May 01; 39(4):1257-60. PubMed ID: 17524948
    [Abstract] [Full Text] [Related]

  • 80.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.